.Piers Morgan when are we doing the interview you promised me?

Let's review #TNT Total Neoadjuvant Treatment and Organ Preservation in #Rectal #Cancers. 1. PRODIGE23 - Induction CT + CRT 2. PROSPECT - No RT & Mid/upper only 3. OPRA - Induction CRT CT Ph2 4. OPERA - Contact Brachy Boost 5. MORPHEUS - HDR BT boost #crcsm #Oncology

🧵 Rectal cancer is not one disease. Tumor location should shape treatment. A new JCO review argues that low- and mid-rectal cancers need different neoadjuvant strategies, with major implications for organ preservation, RT use, and QoL. 📍 Low-rectal cancers Goal: maximize

Rectal cancer treatment is moving toward DE-ESCALATION. • dMMR → Immunotherapy first • Upper/Mid rectum → Radiation may be omitted • Lower rectum → Organ preservation (OPRA watch-and-wait) Biology + anatomy now guide therapy. #MVOnco #RectalCancer #Oncology

The inaugural South-East Mathematics Olympiad Competition Grand Finale was held on Saturday, 7 March 2026 in Enugu, Nigeria. The Olympiad aimes to promote excellence in mathematics and STEM education among young students in the South-East region. It was convened by education

Lung cancer staging always felt confusing to me… until I learnt the simple 3-4-5 rule 👇 • ≤3 cm → IA • 3–4 cm → IB • 4–5 cm → IIA IA → No chemo IB → Gray zone ≥II → Adjuvant chemo Nodes ↑ stage Metastasis → Stage IV #MVOnco #LungCancer

ALINA Trial 👇 Adjuvant Alectinib vs Platinum Chemo in resected ALK+ NSCLC • DFS HR 0.24 • 2-yr DFS 93.8% vs 63% • CNS relapse ↓ 78% Targeted therapy moving earlier in curative lung cancer treatment #MVOnco #LungCancer #ThoracicOncology

ADAURA vs ALINA 👇 Adjuvant targeted therapy in oncogene-driven NSCLC • DFS HR 0.23 vs 0.24 • Strong CNS protection • ADAURA: add TKI after chemo • ALINA: replace chemo with TKI Targeted therapy is moving into curative lung cancer care #MVOnco #LungCancer #ThoracicOncology

Oral paclitaxel (DHP107) was non-inferior to IV paclitaxel in oncologic outcomes; it eliminates the need for IV infusion and results in less neuropathy, but is associated with higher hematologic and gastrointestinal toxicity. OPTIMAL trial full text👇 annalsofoncology.org/article/S0923-…

Do you get upfront brain MRI as part of staging in asymptomatic metastatic HER2+ or triple negative breast cancer? #bcsm Dr Sarah Sammons Paolo Tarantino Bijoy Telivala Santhosh Ambika Yakup Ergün Hope Rugo VIRGINIA KAKLAMANI Matteo Lambertini, MD PhD Erika Hamilton, MD, FASCO Rebecca Shatsky, MD Susan dent

FYI

PD-L1 predicts in metastatic… but not early cancer. Why? • Metastatic → exhausted immunity • Needs PD-L1 removal • Early → strong immunity • Builds new response • Same shield, different outcome #MVOnco #Oncology #Immunotherapy

Exercise after a cancer diagnosis may improve survival. A pooled analysis of 17,141 cancer survivors across 6 cohorts shows that post-diagnosis physical activity is associated with lower cancer mortality. 🏃‍♂️ Even small amounts of activity helped. 📊 Key findings • Any

WHO 2021 changed glioma forever Same histology ≠ same treatment • IDH, 1p/19q, MGMT drive decisions • From observation → RT → chemo → delay strategies Think molecular → treat smarter 🧠 #MVOnco #NeuroOncology #Glioma

🔬✨ Molecular Classification of Breast Cancer — Made Visual & Easy 🧬 From hormone-driven luminal tumors to aggressive triple-negative and claudin-low variants, this chart connects IHC profile + morphology + prognosis in one glance. #Pathology #BreastCancer #MolecularPathology

If you remember only one thing from BRCA biology, remember this👇 • BRCA1 → detects DNA damage • BRCA2 → repairs DNA • PARP → fixes small damage Block PARP + lose BRCA2 → no repair left → cell dies 👉 That’s why PARP works best in BRCA2 #MVOnco #Oncology #MedOnc

Kindly register for this

Today I learnt 👇 Why 5-FU is less effective in dMMR CRC Same drug. Same DNA damage. But without MMR, damage isn’t recognized → less apoptosis. Not true resistance—failure of damage sensing. #MVOnco #CRC #Oncology

More hope for lung cancer. Targeted therapy … way to go ✅